Three NOAC antidotes have been investigated: idarucizumab (Praxbind, approved by the FDA); andexanet alfa (andexanet, Biologics License Application under FDA review), and ciraparantag (in phase II ...

Andexanet alfa also will not have to be used that often, but the potential pool of patients is larger than for idarucizumab. “It’s a small fraction of patients that develop major life-threatening ...

The results of two previous studies of anticoagulation reversal in patients with acute major bleeding were recently reported; one with idarucizumab for dabigatran reversal 11 and another with ...

Portola's andexanet alfa and Boehringer Ingelheim's idarucizumab are both due to be filed for approval this year, with big potential implications for novel oral anticoagulants.

Market: Analysis assumes andexanet alfa will be used by 30% of the 100,000 patients with the indication in 2016 and grow to 60% of the 500,000 patients in 2020.

April 4 (Reuters) - Portola Pharmaceuticals Inc * Portola pharmaceuticals enters into clinical collaboration agreement with daiichi sankyo to develop andexanet alfa with edoxaban in japan ...